This chapter analyzes the recent financial performance and market strategies of companies in the GLP-1 drug space, particularly focusing on the sales struggles faced by a specific firm amidst price concessions. The discussion covers competitive positioning between pharmaceutical giants Novo and Lilly, alongside the evolving perceptions of GLP-1 drugs as they relate to obesity and diabetes management. Personal anecdotes and community impacts are explored, revealing how these medications are transforming local economies and healthcare practices.
Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.
Madison Muller, Bloomberg Health Reporter, on Eli Lilly earnings and her Big Take: What It’s Like When Ozempic Takes Over an Entire Town. Kevin Near, Bloomberg Intelligence Senior Media Associate Analyst, on Warner-Discovery Earnings/Paramount before earnings. Greg Petro, CEO of First Insight, on the role of social media, its biasness in guiding decision-making for consumers. And we Drive to the Close with Jayson Bronchetti, CIO at Lincoln Financial
Hosts: Carol Massar and Matt Miller. Producer: Paul Brennan and Sebastian Escobar
See omnystudio.com/listener for privacy information.